Keyphrases
4-fold
12%
A/H1N1 Virus
12%
Adverse Events
12%
Allogeneic Hematopoietic Stem Cell Transplant Recipients
12%
Antibody Inhibition
12%
Daily Diary
12%
End of Treatment
12%
Fold Increase
12%
Hemagglutinin Antibodies
12%
Hematopoietic Stem Cell Transplant
12%
High Risk
12%
Illness
12%
Influenza
25%
Influenza Incidence
12%
Influenza Prophylaxis
100%
Influenza-like Illness
12%
Intent-to-treat
12%
Kidney
12%
Laboratory Confirmation
12%
Laboratory-confirmed Influenza
12%
Liver
12%
Liver-kidney Transplant
12%
Once-daily
12%
Oseltamivir
100%
Oseltamivir-resistant
12%
Placebo
62%
Placebo Groups
12%
Protective Efficacy
12%
Quantitative PCR
12%
Serious Adverse Events
12%
Serology
12%
Severe Influenza
12%
Solid Organ Transplant Recipients
25%
Transplant Organs
12%
Transplant Recipients
100%
Vaccination
12%
Viral Culture
12%
Weight-based Dosing
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
22%
Disease
11%
Hemagglutinin
11%
Influenza
11%
Influenza A Virus (H1N1)
11%
Oseltamivir
100%
Placebo
66%
RNA Directed DNA Polymerase
11%